Sex differences in treatment and outcomes of patients with in-hospital ST-elevation myocardial infarction

Julia Stehli MD1,2 | Diem Dinh PhD3 | Misha Dagan MD4 | Ron Dick MBBS2 | Stephanie Oxley RN2 | Angela Brennan RN3 | Jeffrey Lefkovits MBBS1,5 | Stephen J. Duffy MBBS PhD1,6 | Sarah Zaman MBBS, PhD7,8,9

1Nursing and Health Sciences, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia
2Epworth HealthCare, Richmond, Victoria, Australia
3School of Public Health and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia
4Department of General Medicine, The Alfred Hospital, Melbourne, Victoria, Australia
5Department of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
6Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia
7School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
8Westmead Applied Research Centre, University of Sydney, Sydney, New South Wales, Australia
9Department of Cardiology, Westmead Hospital, Sydney, New South Wales, Australia

Correspondence
Sarah Zaman, MBBS, PhD, Westmead Hospital, Hawkesbury Rd, Westmead, Sydney, NSW 2145, Australia.
Email: sarah.zaman@sydney.edu.au

Funding information
Epworth Medical Foundation,
Grant/Award Number: N/A

Abstract

Background and Hypothesis: Two cohorts face high mortality after ST-elevation myocardial infarction (STEMI): females and patients with in-hospital STEMI. The aim of this study was to evaluate sex differences in ischemic times and outcomes of in-hospital STEMI patients.

Methods: Consecutive STEMI patients treated with percutaneous coronary intervention (PCI) were prospectively recruited from 30 hospitals into the Victorian Cardiac Outcomes Registry (2013–2018). Sex discrepancies within in-hospital STEMIIs were compared with out-of-hospital STEMIIs. The primary endpoint was 12-month all-cause mortality. Secondary endpoints included symptom-to-device (STD) time and 30-day major adverse cardiovascular events (MACE). To investigate the relationship between sex and 12-month mortality for in-hospital versus out-of-hospital STEMIIs, an interaction analysis was included in the multivariable models.

Results: A total of 7493 STEMI patients underwent PCI of which 494 (6.6%) occurred in-hospital. In-hospital versus out-of-hospital STEMIIs comprised 31.9% and 19.9% females, respectively. Female in-hospital STEMIIs were older (69.5 vs. 65.9 years, p = .003) with longer adjusted geometric mean STD times (104.6 vs. 94.3 min, p < .001) than men. Female versus male in-hospital STEMIIs had no difference in 12-month mortality (27.1% vs. 20.3%, p = .92) and MACE (22.8% vs. 19.3%, p = .87). Female sex was not independently associated with 12-month mortality for in-hospital STEMIIs which was consistent across the STEMI cohort (OR: 1.26, 95% CI: 0.94–1.70, p = .13).

Conclusions: In-hospital STEMIIs are more frequent in females relative to out-of-hospital STEMIIs. Despite already being under medical care, females with in-hospital STEMIIs experienced a 10-min mean excess in STD time compared with males, after adjustment for confounders. Adjusted 12-month mortality and MACE were similar to males.

KEYWORDS
female, in-hospital STEMI, sex discrepancies, symptom-to-device time, women
1 | INTRODUCTION

Coronary artery disease is the leading cause of death worldwide. Despite advancements in medical therapy and device technology, patients with ST-elevation myocardial infarction (STEMI) continue to suffer from high mortality. Rapid reperfusion is key in the treatment of STEMI with time from symptom onset to revascularization closely linked to outcomes. Two groups of patients with STEMI who demonstrate a particularly poor prognosis are females and patients with so-called “in-hospital STEMI,” that is, STEMI that happens while the patient is already admitted to the hospital. With regard to females, factors associated with poorer outcomes include significantly longer ischemic times in females compared with males as well as more bleeding and less guideline-directed medical therapy. Similarly, patients with in-hospital STEMI have been found to have longer ischemic times compared with patients presenting with out-of-hospital STEMI. Further, both female patients, and those with in-hospital STEMI, are older and have more comorbidities. They are both less likely to undergo invasive diagnostic management as well as to be treated with percutaneous coronary intervention (PCI).

Despite these concerning data, patients with in-hospital STEMI have been under-researched, with less than a handful of studies conducted. The topic is of critical importance during the current coronavirus-19 pandemic: Acute cardiac injury is present in 17% of patients with COVID-19 and is predictive of in-hospital mortality in this patient group. Importantly, STEMI do occur both as the first sign of COVID-19 or in-hospital patients admitted for COVID-19.

In particular, no research has been undertaken with regard to female patients with in-hospital STEMI and possible sex disparities in this patient group and as compared with overall STEMI cohorts. The aim of this study was to evaluate sex differences in ischemic times and outcomes of patients with in-hospital STEMI in a large, multicenter, prospective registry.

2 | METHODS

From 2013 to 2018, consecutive patients presenting with STEMI who all underwent PCI were prospectively recruited into the Victorian Cardiac Outcomes Registry (VCOR). VCOR is an Australian, state-based clinical quality registry designed to monitor the performance and outcome of PCI in Victoria. VCOR was established in 2012 and is engaged with all 30 Victorian PCI-capable hospitals (13 public [i.e., government-funded] and 17 private) with all patients undergoing PCI or attempted PCI entered into the registry. VCOR collects baseline demographic, procedural characteristics, in-hospital, and 30-day outcome data on all patients who undergo PCI at a given facility through a secure web-based data collection system. All data entry personnel are registered with VCOR and data are entered in real time as the patient progresses through the hospital admission. Data integrity is ensured with regular audit activities conducted by the central registry. VCOR is funded by the Victorian Department of Health and Human Services. Twelve-month mortality was obtained through linkage of the database to the Australian Registry of Births, Deaths and Marriages. The study was approved by the Institutional Human Research Ethics Committee with an opt-out consent. The investigations were in accordance with the Declaration of Helsinki.

Consecutive patients who received successful or attempted PCI for a STEMI were included. At the time of entering the patient into the VCOR database, STEMI was defined as elevated cardiac biomarkers and new ST-segment elevation in two or more contiguous leads. The clinical definition was based on a “maximal concentration of Troponin T or I above the MI diagnostic limit on at least one occasion within 24 hours from the index clinical event and ST-segment elevation in the ECG, equal to the Fourth Universal Definition of Myocardial Infarction.” In-hospital STEMI was defined based on the timing of onset of symptoms occurring after the time of hospital admission. As per VCOR definition, the time recorded for symptom onset was when the patients advised the hospital staff of their symptoms. Out-of-hospital STEMI included all other STEMI where symptom onset occurred before presentation to hospital. For the analysis of symptom-to-device (STD) time, the following patients were excluded from the analysis: (i) patients without a recorded time of symptom onset, (ii) patients who presented for PCI more than 12 h after symptom onset, (iii) patients who had symptom onset while admitted in a non-PCI capable hospital (for the in-hospital STEMI), and (iv) patients who presented to a non-PCI capable hospital (for the out-of-hospital STEMI, outlined in Figure 1).

Sex discrepancies in in-hospital STEMI patients were analyzed and compared with sex discrepancies in out-of-hospital STEMI patients for the primary endpoint of 12-month all-cause mortality. Secondary endpoints included STD time, 30-day all-cause mortality, major adverse cardiovascular events (MACE, consisting of all-cause death, new or recurrent MI, stent thrombosis or target vessel revascularization), major adverse cardiovascular and cerebrovascular events (MACCE, consisting of MACE and stroke), major bleeding (consisting of Types 3 and 5 according to the Bleeding Academic Research Consortium definition), recurrent MI, new heart failure (defined according to clinical signs), new renal impairment at 30 days, and length of hospital stay.

STD time was defined as the time span between the onset of symptoms and the first device used to re-establish coronary blood flow during PCI.

The European Society of Cardiology (ESC) guidelines recommend a time of ≤60 min from STEMI diagnosis to device passage in patients presenting to a PCI-capable hospital. Additionally, FMC-to-electrocardiogram (ECG) acquisition time is recommended at ≤10 min. A FMC-to-ECG acquisition time of ≤10 min and a time span from STEMI diagnosis to reperfusion of ≤60 min would result in an ideal STD time of ≤70 min for in-hospital STEMI. Accordingly, to assess for reperfusion delays, the percentage of female and male in-hospital STEMI patients achieving an STD time ≤70 min was analyzed. The American Heart Association (AHA) guidelines recommend a first medical contact (FMC)-to-device time of ≤90 min in patients presenting to a PCI-capable hospital. With no in-hospital STEMI
guidelines available, the time of symptom onset (as patients are already admitted under medical care) can take the place of FMC. Accordingly, to assess for sex discrepancies in reperfusion delays, the percentage of male and female in-hospital STEMI patients achieving an STD time ≤90 min was analyzed.6

Preprocedural creatinine was collected up to 60 days before the PCI and the Cockcroft-Gault formula used to determine the estimated glomerular filtration rate (eGFR). New renal impairment was defined as an absolute rise of serum creatinine ≥44.2 μmol/L or an increase of ≥25% up to 5 days after the index PCI when compared with baseline creatinine. Left ventricular ejection fraction (LVEF) was collected during the index STEMI admission or up to 30-day post discharge. Moderate LV dysfunction was defined as LVEF < 45%, severe LV dysfunction as LVEF < 30%. New heart failure was defined as clinical evidence of heart failure (i.e., new paroxysmal nocturnal dyspnea, new dyspnea on exertion, chest X-ray showing pulmonary congestion or dyspnea treated with medical therapy for heart failure). Complex lesions included type B2 and C lesions according to American College of Cardiology/AHA classification guidelines. Mechanical ventricular support included intra-aortic balloon pump, left ventricular assist device, and/or extracorporeal membrane oxygenation.

Associations in categorical variables were analyzed with χ² or Fisher’s exact tests as appropriate and expressed as number and percentage. Continuous variables were analyzed with a t test and expressed as mean and standard deviation. Since the distributions of presentation and revascularization times were highly skewed, their data were log-transformed for analysis and back to determine an estimated geometric mean. Along with sex, variables determined a priori to be included in the multivariate models were age, diabetes, eGFR, previous PCI and/or coronary artery bypass grafting, history of cerebrovascular disease, LVEF, out-of-hospital and in-hospital cardiac arrest, cardiogenic shock, graft lesions, stent thromboses, and occurrence time of symptom onset. The variables forced into and retained in the model were determined based on prior literature and experience that these factors are known to influence MACE and all-cause mortality.

To investigate the relationship between sex and 12-month mortality outcomes for out-of-hospital STEMI patients compared with in-hospital STEMI patients, interaction was utilized. A p value <.05 was considered statistically significant for all analyses. Statistical analyses were performed using Stata version 14.

3 | RESULTS

A total of 7493 patients underwent PCI for the treatment of STEMI of which 494 (6.6%) were in-hospital STEMI. Of these, 158 patients (31.9%) were female compared with 1394 female patients (19.9%) in the out-of-hospital STEMI group. PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

Female and male in-hospital STEMI patients had similar rates of stent thrombosis (17.1% vs. 16.4%). Female in-hospital STEMI patients were significantly less likely to receive statins (p = .030) and P2Y12 inhibitors (p = .040, presented in Table 2).

Female patients had significantly longer unadjusted (119.4 vs. 105.2 min, p < .001) and adjusted (104.6 vs. 94.3 min, p < .001) geometric mean STD time than male patients. Only 27% of female in-hospital STEMI patients achieved an STD time of ≤70 min compared with 32% of male patients (displayed in Figure 2). Only 44% of female in-hospital STEMI patients achieved an STD time ≤90 min compared with 49% of male in-hospital STEMI patients.

Female patients presenting with in-hospital STEMI had numerically worse outcomes at 12-months (all-cause mortality: 27.1% vs. 20.3%, p = .92) and 30 days (all-cause mortality: 13.9% vs. 11.9%, p = .43; MACE: 22.8% vs. 19.3%, p = .87; MACCE: 24.1% vs. 20.8%,
Both groups have been described to suffer worse outcomes after a STEMI. However, data on in-hospital STEMI are scant and no previous studies have addressed sex differences in this unique cohort. This is surprising given that patients who are hospitalized for a noncardiac cause have a 40–50 times higher likelihood of suffering a STEMI compared with people in the community. Of interest, women made up a larger proportion (31.9%) of all STEMI cases occurred in patients already admitted to the hospital, consistent with the 5%–8% described in previous literature. Of interest, women made up a larger proportion (31.9%) of all STEMI cases occurred in patients already admitted to the hospital, consistent with the 5%–8% described in previous literature. Of interest, women made up a larger proportion (31.9%) of all STEMI cases occurred in patients already admitted to the hospital, consistent with the 5%–8% described in previous literature.

### DISCUSSION

This is the first study to assess sex differences in patients with an in-hospital STEMI, utilizing a large registry that captured all STEMI patients who were treated with PCI. The main findings of our study were that: (i) women comprised a larger proportion of patients with in-hospital STEMI compared with out-of-hospital STEMI; (ii) women with in-hospital STEMI had significantly longer adjusted ischemic times compared with men and received significantly less Ticagrelor and statins; (iii) there was no significant interaction between sex and in-hospital symptom onset for 12-month and 30-day mortality, MACE, MACCE, and major bleeding and (iv) female sex was not independently associated with higher 12-month mortality for in-hospital STEMI patients.

Two groups of patients with STEMI are known to be distinct in their characteristics: women and patients with in-hospital STEMI.
onset to FMC or hospital arrival. In our inpatient STEMI cohort, significant sex delays were seen, despite patients being already admitted to the hospital. However, similar factors may be at play. Females experience a higher rate of associated symptoms and therefore healthcare providers are less likely to attribute their chest pain to a STEMI compared with males. The ESC guidelines state that patients with suspected STEMI should receive an ECG within 10 min of FMC with an ECG-to-device time ≤60 min. This would equate to an STD time of ≤70 min for patients with in-hospital STEMI. If we were to use the same criteria for our female patients with in-hospital STEMI, only 27% achieved the recommended STD time of ≤70 min, compared with 32% of males. According to the ACC/AHA, an STD time ≤90 min was achieved in 44% of female in-hospital STEMI patients, compared with 49% in male in-hospital STEMI patients. Similar to out-of-hospital patients, check-lists and protocols as well as healthcare professional education, could help establish equal care for females, as for male patients. The current study included only patients with in-hospital STEMI who were deemed suitable for and underwent PCI. Previous studies that included all-comers, not just those treated with PCI, demonstrated women made up an even higher proportion of patients with in-hospital STEMI at 44%−47%. We know that female patients presenting with standard out-of-hospital STEMI are less likely to undergo PCI. Given the 12%−15% difference in female proportions between our study, and those on all-comers, we speculate that less women with in-hospital STEMI are being taken to the catheterization laboratory. As to if this is a true sex difference, or a marker of female in-hospital STEMIs being older with higher comorbid burden, requires further study.

Consistent with studies in all-comer patients with STEMI, women with an in-hospital STEMI were less likely to be discharged on Ticagrelor compared with men. This is likely due to the higher bleeding risk in women compared with men. However,
while studies show that P2Y12 inhibitors lead to more bleeding in women, this is mostly true for patients with stable CAD. On the contrary, women with STEMI benefit equally from a potent P2Y12 inhibitor compared with men. In addition, 12% of female patients with in-hospital STEMI did not receive high-dose statin therapy, which was significantly different from males. This is particularly unfortunate given the unequivocally demonstrated benefits of statin therapy in secondary prevention. While this may reflect underlying comorbid conditions two factors may also explain it: first, patients with in-hospital STEMI are usually not under the primary care of a cardiologist and, second, treating doctors underestimate women’s risk for recurrent events.

5 | LIMITATIONS

Our study has certain limitations. First, the registry does not provide data about the condition for which patients with in-hospital STEMI were hospitalized and therefore cannot assess the impact of this on survival. Second, our registry only captures patients with STEMI treated with PCI; hence, we cannot comment on sex differences that occur in admitted patients who did not undergo revascularization, which can lead to selection and survivor bias. However, it is well known that females with STEMI are less likely to undergo PCI, which would only strengthen our results, since STEMI patients not taken to the catheterization laboratory are likely to have an even poorer outcome. Third, the ability to detect small sex differences was limited by the in-hospital STEMI sample size.

Lastly, the data were not assessed for multiple recruitments; however, only 5% of stent thromboses resulting in an in-hospital STEMI occurred during the same admission as an initial PCI.

6 | CONCLUSIONS

Female in-hospital STEMI patients suffer from high MACE, mortality, bleeding, and recurrent MI with no statistical difference in outcomes compared with males. However, female patients with in-hospital STEMI experienced an average 10-min delay from symptom onset to reperfusion compared with males, after adjustment for confounders. Raising awareness of sex differences in this under-studied population of patients with in-hospital STEMI is required to improve outcomes and further narrow the gap.

ACKNOWLEDGMENT

Funding for this study was provided by the Epworth Medical Foundation.

CONFLICT OF INTERESTS

Julia Stehli is supported by a Monash University scholarship. Ron Dick receives teaching and travel grants from Abbott, Medtronic, and Boehringer. He serves on the advisory board of Astra Zeneca. Stephen J. Duffy is proctor for Medtronic and his work is supported...
by a grant (11111170) from the National Health and Medical Research Council of Australia. Sarah Zaman is supported by a fellowship (101993) from the National Heart Foundation of Australia. Sarah Zaman has obtained research funding from Abbott Vascular, Biotronik Australia, and Medtronic Australia and speaking honoraria from AstraZeneca, Boehringer Ingelheim, and Amgen and consulting fees from Medtronic. All other authors have no conflict of interests.

**DATA AVAILABILITY STATEMENT**

The deidentified data analyzed for the purpose of this study are available upon request to the VCOR Data Access, Research and Publications Committee by emailing vcor@monash.edu.

**ORCID**

Julia Stehli http://orcid.org/0000-0003-3089-1062

Sarah Zaman https://orcid.org/0000-0001-6289-583X

**REFERENCES**

1. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019; 12:e005375. doi:10.1161/circoutcomes.118.005375

2. Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014;35:1957-1970. doi:10.1093/eurheartj/ehu529

3. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.

4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. doi:10.1093/eurheartj/ehx393

5. Scholz KH, Maier SKG, Maier LS, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J. 2018;39:1065-1074. doi:10.1093/eurheartj/ehy004

6. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-555. doi:10.1161/CIR.0b013e3182742e84

7. Venetanos D, Sederholm Lawesson S, Alfredsson J, et al. Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the cathe-terisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMJ Open. 2017;7:e015241. doi:10.1136/ bmjopen-2016-015241

8. Berger JS, Elliott L, Gallup D, et al. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302:874–882. doi:10.1001/jama.2009.1227

9. Bucholz EM, Normand SL, Wang Y, Ma S, Lin H, Krumholz HM. Life expectancy and years of potential life lost after acute myocardial infarction by sex and race: a cohort-based study of medicare beneficiaries. J Am Coll Cardiol. 2015;66:645-655. doi:10.1016/j.jacc.2015.06.022

10. Vincent L, Ariza-Solé A, Alegre O, et al. Octogenarian women with acute coronary syndrome present frailty and readmissions more frequently than men. Eur Heart J Acute Cardiovasc Care. 2019;8:252-263. doi:10.1177/2048872618798226

11. Cenko E, Yoon J, Kedev S, et al. Sex differences in outcomes after STEMI: effect modification by treatment strategy and age. JAMA Intern Med. 2018;178:632-639. doi:10.1001/jamainternmed.2018.0514

12. Kosmidou I, Leon MB, Zhang Y, et al. Long-term outcomes in women and men following percutaneous coronary intervention. J Am Coll Cardiol. 2020;75:1631-1640. doi:10.1016/j.jacc.2020.01.056

13. Dai X, Bumgarner J, Spangler A, Meredith D, Smith SC, Stouffer GA. Acute ST-elevation myocardial infarction in patients hospitalized for noncardiac conditions. J Am Heart Assoc. 2013;2:e000004. doi:10.1161/JAHA.113.000004

14. Jaski BE, Grigoriadis CE, Dai X, et al. Factors associated with indi-cibility for PCI differ between inpatient and outpatient ST-elevation myocardial infarction. J Interv Cardiol. 2016;29:363-369. doi:10.1111/joic.12306

15. Kaul P, Federspiel JJ, Dai X, et al. Association of inpatient vs outpatient onset of ST-elevation myocardial infarction with treatment and clinical outcomes. JAMA. 2014;312:1999-2007. doi:10.1001/jama.2014.15236

16. Stehli J, Martin C, Brennan A, Dinh DT, Lefkovits J, Zaman S. Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coro-nary intervention. J Am Heart Assoc. 2019;8:e012161. doi:10.1161/JAHA.119.012161

17. D’Onofrio G, Safdar B, Lichtman JH, et al. Sex differences in re-perfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study. Circulation. 2015;131: 1324-1332. doi:10.1161/CIRCULATIONAHA.114.012293

18. Sederholm Lawesson S, Isaksson RM, Ericsson M, Angerud K, Thylen L. SymTime Study G. Gender disparities in first medical contact and delay in ST-elevation myocardial infarction: a prospective multicentre Swedish survey study. BMJ Open. 2018;8:e020211. doi:10.1136/bmjopen-2017-020211

19. Yu J, Baber U, Mastor I, et al. Sex-based differences in cessation of dual-antiplatelet therapy following percutaneous coronary intervention with stents. JACC Cardiovasc Interv. 2016;9:1461-1469. doi:10.1016/j.jcin.2016.04.004

20. Wilkinson C, Bebb O, Dondo TB, et al. Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. Heart. 2019;105:516-523. doi:10.1136/heartjnl-2019-313959

21. Zhao M, Vaartjes I, Graham I, et al. Sex differences in risk factor management of coronary heart disease across three regions. Heart. 2017;103:1587-1594. doi:10.1136/heartjnl-2017-311429

22. Garberich RF, Traverse JH, Claussen MT, et al. ST-elevation myocardial infarction diagnosed after hospital admission. Circulation. 2014;129:1225-1232. doi:10.1161/CIRCULATIONAHA.113.005568

23. Alabas OA, Gale CP, Hall M, et al. Sex differences in treatments, relative survival, and excess mortality following acute myo-cardial infarction: national cohort study using the SWEDEHEART Registry. J Am Heart Assoc. 2017;6:6. doi:10.1161/JAHA.117.007123

24. Hansen KW, Soerensen R, Madsen M, et al. Developments in the invasive diagnostic-therapeutic cascade of women and men with acute coronary syndromes from 2005 to 2011: a nationwide cohort study. BMJ Open. 2015;5:e007785. doi:10.1136/bmjopen-2015-007785

25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective
cohort study. Lancet. 2020;395:1054-1062. doi:10.1016/s0140-6736(20)30566-3

26. Stefanini GG, Montorfano M, Trabattoni D, et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020;141:2113-2116. doi:10.1161/circulationaha.120.047525

27. Stub D, Lefkovits J, Brennan AL, et al. The establishment of the Victorian Cardiac Outcomes Registry (VCOR): monitoring and optimising outcomes for cardiac patients in Victoria. Heart Lung Circ. 2018;27:451-463. doi:10.1016/j.hlcc.2017.07.013

28. Cox N, Brennan A, Dinh D, et al. Implementing sustainable data collection for a cardiac outcomes registry in an Australian public hospital. Heart Lung Circ. 2018;27:464-468. doi:10.1016/j.hlcc.2017.01.023

29. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231-2264. doi:10.1016/j.jacc.2018.08.1038

30. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155-2165. doi:10.1056/NEJMoaj0908610

31. Dai X, Kaul P, Smith SC Jr., Stouffer GA. Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. Nat Rev Cardiol. 2016;13:148-154. doi:10.1038/nrcardio.2015.165

32. Zahn R, Schiele R, Seidl K, et al. Acute myocardial infarction occurring in versus out of the hospital: patient characteristics and clinical outcome. Maximal Individual TherApy in Acute Myocardial Infarction (MITRA) Study Group. J Am Coll Cardiol. 2000;35:1820-1826. doi:10.1016/s0735-1097(00)00629-x

33. Bugiardini R, Ricci B, Cenko E, et al. Delayed care and mortality among women and men with myocardial infarction. J Am Heart Assoc. 2017;6.d. doi:10.1161/JAHA.117.005968

34. Lichtman JH, Leifheit EC, Safdar B, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: evidence from the VIRGO Study (variation in recovery: role of gender on outcomes of young AMI patients). Circulation. 2018;137:781-790. doi:10.1161/CIRCULATIONAHA.117.031650

35. Kirchberger I, Heier M, Kuch B, Wende R, Meisinger C. Sex differences in patient-reported symptoms associated with myocardial infarction (from the population-based MONICA/KORA Myocardial Infarction Registry). Am J Cardiol. 2011;107:1585-1589. doi:10.1016/j.amjcard.2011.01.040

36. Huded CP, Johnson M, Kravitz K, et al. 4-step protocol for disparities in STEMI care and outcomes in women. J Am Coll Cardiol. 2018;71:2122-2132. doi:10.1016/j.jacc.2018.02.039

37. Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc. 2014;3:e000849. doi:10.1161/JAHA.114.000849

38. Cenko E, van der Schaar M, Yoon J, et al. Sex-related differences in heart failure after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019;74:2379-2389. doi:10.1016/j.jacc.2019.08.1047

39. Turgeon RD, Koshman SL, Youngson E, et al. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020;180:420-428. doi:10.1001/jamainternalmed.2019.6447

40. Lau ES, Braunwald E, Murphy SA, et al. Potent P2Y12 inhibitors in men versus women: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2017;69:1549-1559. doi:10.1016/j.jacc.2017.01.028

41. Chichareon P, Modolo R, Kerkmeyer L, et al. Association of sex with outcomes in patients undergoing percutaneous coronary intervention: a subgroup analysis of the GLOBAL LEADERS randomized clinical trial. JAMA Cardiol. 2019;4. doi:10.1001/jamacardio.2019.4296

42. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-1800. doi:10.1056/NEJMoa1500857

43. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278. doi:10.1016/s0140-6736(05)67394-1

44. Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12:e005562. doi:10.1161/CIRCOUTCOMES.118.005562

45. Khra S, Kolte D, Gupta T, et al. Temporal trends and sex differences in revascularization and outcomes of ST-segment elevation myocardial infarction in younger adults in the United States. J Am Coll Cardiol. 2015;66:1961-1972. doi:10.1016/j.jacc.2015.08.865

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Stehli J, Dinh D, Dagan M, et al. Sex differences in treatment and outcomes of patients with in-hospital ST-elevation myocardial infarction. Clin Cardiol. 2022; 45:427-434. doi:10.1002/clc.23797